Urology 1999,54(3):567–72.PubMedCrossRef 10. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993,143(2):401–9.PubMed 11. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999,5(6):623–8.PubMedCrossRef 12. ldfarb SB, Hudis C, Dickler MN: Bevacizumab in metastatic breast cancer:
when may it be used? Ther Adv Med Oncol 2011,3(2):85–93. 13. Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F: Bevacizumab in non-small cell lung cancer. Drugs 2008,68(6):737–46.PubMedCrossRef 14. deGramont A, Van Cutsem E: Investigating the potential of bevacizumab in other indications: metastatic IDO inhibitor renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005,69(suppl 3):46–56.CrossRef 15. Amselem L, Cervera E, Díaz-Llopis M, Montero J, Garcia-Pous M, Udaondo P, García-Delpech S, Salom D: Intravitreal bevacizumab
(Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. Eye 2007,21(4):566–567.PubMed 16. Zondor SD, Medina PJ: see more Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother. 2004,38(7–8):1258–1264.PubMed 17. Brekken R, Overholser J, Stastny V, Waltenberger J, Minna JD, Thorpe PE: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-2) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 2000,60(18):5117–5124.PubMed 18. Yang H, Jager MJ, Grossniklaus HE: Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
Invest Ophthalmol Vis Sci 2010,51(6):2835–42.PubMedCrossRef 19. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE: A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular ABT737 expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 2002,5(1–2):35–44.PubMedCrossRef 20. Sheidow TG, Hooper PL, Crukley C, Young J, Heathcote JG: Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br. J. Ophthalmol. 2000,84(7):750–756.PubMedCrossRef FER 21. Boyd SR, Tan D, Bunce C, Gittos A, Neale MH, Hungerford JL, Charnock-Jones S, Cree IA: Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouringuveal melanoma: identification of a potential therapeutic window. Br. J. Ophthalmol. 2002,86(4):448–452.PubMedCrossRef 22. Crosby MB, Yang H, Gao W, Zhang L, Grossniklaus HE: Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma. Br. J. Ophthalmol. 2011,95(1):112–7.PubMedCrossRef 23.